Information on the Certification Procedure Dr P. Poukens-Renwart Certification of Substances Division, EDQM P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council.

Slides:



Advertisements
Similar presentations
1 Harmonisation of requirements: where we are Erik Waterdrinker, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.
Advertisements

Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Dr. Raghuveer Pharma Consultants D R P C Quality. Perfection. Confidentiality. D R P C Quality. Perfection. Confidentiality. 1.
Certification of Substances Division,
BROMI Variations Training Meeting 8th May 2008 Case Study Session BROMI VARIATIONS.
U.S. Pretrial Services and Probation Office Northern District of Ohio.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Experience of Pre-Qualification Program.
GMP Document and Record Retention
ICH Q11 – Definisjon av startmaterialer – Fleksibilitet og dokumentasjonskrav Andreas Sundgren LMI 17. april 2012.
1 XXXXXXXXXXXXXXXXXXX, Malaysia, XXXXXX September, S.3.2 Impurities, Malaysia, 29 September 2011 Options for submitting API data to support.
Manufacturing Process
Batch Reworking and Reprocessing
Federal agency for medicines and health products EXCIPIENTS IN THE LABLE AND PACKAGE LEAFLET OF HOMEOPATHIC MEDICINAL PRODUCTS Patricia Bodart – 23 October.
World Health Organization
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
©2014 Factorytalk Co., Ltd. Proprietary and Confidential eCTD Specification 17 July 2014.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
| Slide 1 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront Cape.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 QIS/QOS: The new PQP quality templates.
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Good Manufacturing Practices for Blood Establishments
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Integrated Online Research Compliance System (iORC)
Instructions and forms
PROACTIS: Supplier User Guide Contract Management.
Structure of Dossier of Medicinal Product- Q part
Responding to Inspection Findings
API Inspections: the EDQM experience 29 March 2010
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
World Health Organization
ESPON 2013 Programme Info Day on Calls and Partner Café Brussels, 10 May 2012 How to apply: Application Form and Eligibility A Decade of Territorial.
APRE Agency for the Promotion of European Research Lifecycle of an FP 7 project Caterina Buonocore Riga, 13th September, 2007.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Technology Programme Autumn 2005 Autumn 2005 Competition The Application and Assessment Process Peter Miles TUVNEL Ltd.
Quality of Substances for Pharmaceutical Use: The EDQM Certification of Suitability to the European Pharmacopoeia Monographs (CEP) Dr. Susanne Keitel DIA.
Welcome Document Imaging System Training Dial in number: (559) Participant Access Code: #
PRODUCT TRANSFER.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
1 Impurities: Positions of the regulatory authorities (like FDA and EMA) worldwide Dr. Christian Zeine, Warsaw, Nov 18, 2014 Science for a safer world.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Monograph Development Process for the European Pharmacopoeia: How to participate in the work programme of the European Pharmacopoeia Dr Claude Coune Head.
Principles of quality control of registered medicines, non- registered medicines and counterfeits of medical products Jean-Marc Spieser, Head of Department.
WHO Workshop on Assessment of Bioequivalence Data BCS-Biowaivers - Template Dr. Henrike Potthast WHO Workshop on Assessment of.
Open Access and the Wellcome Trust: providing funds for open-access publishing Kathryn Lallu Grants Policy, Liaison and Support Manager Grants Administration.
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
HiLumi LHC is co-funded by the EU FP7 Capacities Programme, Grant Agreement Svet Stavrev (EU Projects Office, CERN) Administrative Manager 17.
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
© AL IPA/EDQM/IDMA Symposium 2007, All rights reserved The Ph. Eur. policy on impurities Dr Andrea Lodi Deputy Head, Laboratory Department, EDQM, Council.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
IPA-EDQM Mumbai 11/2007 ©2007 EDQM, Council of Europe 1 Content of the application for a CEP Hélène BRUGUERA Deputy Head Certification of Substances Division.
Science & Engineering Research Support soCiety Guest Editor Guidelines for Special Issue 1. Quality  Papers must be double -blind.
International conference Quality of Active Pharmaceutical Ingredients Hyderabad, September 2009 API Inspections: the EDQM experience – 7 September.
API’s Registration Process supported by Apteka-95 Pharmaceutical Firm, Ltd. API’s Registration Process supported by Apteka-95 Pharmaceutical Firm, Ltd.
Module 14Slide 1 of 23 WHO - EDM Basic Principles of GMP Active Pharmaceutical Ingredients Part Three, 18.
Consumers, Health, Agriculture and Food Executive Agency 3rd Health Programme The Electronic Submission System (JA 2015) Georgios MARGETIDIS.
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
In the name of God. Common Technical Document On Biotech.
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Dr Pascale POUKENS-RENWART Scientific Officer
Information session SCIENTIFIC NEGOTIATIONS Call FP7-ENV-2013-two-stage "Environment (including climate change)" Brussels 22/05/2013 José M. Jiménez.
World Health Organization
The European Pharmacopoeia and Pharmeuropa
Quality guidelines on impurities
GL 51 – Statistical evaluation of stability data
Presentation transcript:

Information on the Certification Procedure Dr P. Poukens-Renwart Certification of Substances Division, EDQM P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Summary Some deficiencies How to read and use a CEP? Finding information on the procedure Key figures Recent developments Benefits of the procedure P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Deficiencies Observed during the validation process of the application Observed during assessment process of the application and other then those listed in top 10. P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

A complete application requires: Application form (for new application) Single copy of the dossier in English preferably (or French) under CTD format; Quality Overall Summary: use the EDQM template and submit electronic version as Word file Samples: ! new policy: commitment to provide samples upon request from EDQM Electronic submission welcome:NEES (instructions on EDQM website) Send the package to EDQM. Fee to be paid after receipt and invoicing P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Validation at receipt applications are blocked when: 1.Administrative information is not complete 2.Technical information is not sufficient P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Administrative validation at receipt Dossier is blocked when: Dossier not in CTD format QOS is missing or not signed Information from application form is missing: –Names and addresses of the parties involved –Agreement letters Representative agent or when holder ≠ manufacturer –Declaration of Manufacture according to the dossier and GMP (ICH Q7/EU GMP if sterile) –Declaration of Willingness to be inspected Manufacturer, and holder if different –Use of animal (TSE risk or other origin) / human material P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Validation at receipt (cont) Summarise the commercial history - make clear if, and in what product THIS source of API is on the EUROPEAN market. Information on ASMF submitted for the same substance Give as much information as possible (companies, products names, countries, registration dates, marketing dates). --> Impact on Qualification (limits) of impurities P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Validation at receipt (cont) Retest period –Is an Option –Specify the proposed retest period: Justified by stability data Studies according to ICH conditions –Recommended storage conditions –Specify the packaging material P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Technical validation at receipt Applications are blocked when: Reference is made to an old version of the Ph. Eur monograph Description of route of synthesis and/or impurity profile of the starting material is missing Use of Class I solvents without justification and control Unsuitable information on impurities, solvents,… Absence of validation data Quantitative method to replace a non-specific TLC test of the monograph Sterile substances: validation of the sterilisation P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Validation at receipt 23% blocked at this step in June 2009 (up to 38% in 2007 = not suitable to start the evaluation) Application blocked --> the clock does not start until suitable information is given. ! An incomplete application delays the CEP  Read PA/PH/Exp CEP/T (08) 37 Note for applicants: « Procedure for validation of new applications » P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

After evaluation (the clock has started) Most applications require one or several requests for additional information (3% only of applications accepted at the time of first evaluation) Evaluation of additional information takes 4 months ! A deficient application delays the CEP P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Deficiencies: How to avoid them ? Read : PA/PH/ CEP (04) 1 4R issued, February 2007, entitled “Content of the dossier for chemical purity and microbiological quality” It is FREE, It is available on our website and is the Revision of Annex I, Resolution AP-CSP (93) 5 as amended. It describes what we expect to see in the dossier. P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Deficiencies: How to avoid them ? Keep in mind –The scheme is Certification of suitability to the monographs of the EUROPEAN Pharmacopoeia. –References, terminology, etc. should be to the Ph. Eur or at least traceable to it –There is a requirement to show that the monograph is suitable to control the actual quality of your substance. P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Deficiencies: How to avoid them ? Presentation on top ten deficiencies 2008 (9th September 2009) Read summary of the main deficiencies found in the dossiers for Certificates: PA/PH/CEP (08) 11 P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Other deficiencies observed Manufacturing Process Control of Materials Control of Critical steps and Intermediates Stability P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

3.2.S.2.2 Manufacturing Process and Process controls You should provide: Brief outline and flow chart for your process Detailed process description : –typical/maximum batch size –narrative description of the synthesis (incl temperatures, quantities, times etc.) –structure of isolated intermediates P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

3.2.S.2.2 Manufacturing Process and Process Controls Different sites, different manufacturing methods (including alternatives) and reprocessing can be included in one dossier if: the impurity profile of final substance is the SAME -> detailed information to be provided re-working is not allowed (->introduction of new solvents) -> normally this results in a change in the impurity profile P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

3.2.S.2.2 Manufacturing Process and Process Controls For semi-synthetic products:  Fermentation steps involved in synthesis of starting material, must address: Characterisation of fermented starting material, incl. detailed impurity profile, compliance with the GM 1468 Carry-over of fermentation impurities, proteins, DNA,… Use of TSE risk substances in manufacture? P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

3.2.S.2.3 Control of Materials If material of animal origin is used: If a TSE risk substance is involved: CEP will not be granted for a chemical until the TSE risk has been assessed  “Double” CEP The use of animal or human origin material will be mentioned on the CEP and the viral safety risk has to be assessed for the relevant marketing application. P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

3.2.S.2.4 Control of Critical steps and Intermediates Provide sufficient information on the intermediate control and the in-process controls. Especially important if you use this control to avoid a control later in the process!! P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

3.2.S.7 Stability CPMP guideline “Stability testing of existing active substances” (CPMP/QWP/ 122/02 Rev. 1) A retest period is optional (does not block the granting of the CEP) ICH conditions, incl. accelerated conditions Study description - relevant parameters Detailed results Validation of in-house methods (stability indicating) + cross validation with Ph.Eur method Majority of monograph methods are stability indicating but some older methods may need to be supplemented by (validated!) in-house methods P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Conclusions: how to avoid deficiencies? Data given in the dossier should be: –Clear –Concise –Readable –Obtained from recent analysis Use CTD format –Address the requirements of « Content of the Dossier » –Address the deficiencies detailed in this presentation –Implement recent developments if appropriate Provide complete administrative information Visit our website (news and general information) P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

How to read a CEP chemical? Certifies that the quality of a given substance can be suitably controlled by the Ph.Eur. monograph - with additional tests if necessary (stated on the CEP). It DOES NOT certify that a batch or batches of the substance complies with the Pharmacopoeia monograph. It IS NOT a GMP certificate P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

How to read a CEP TSE ? Certifies that the substance complies with the EMEA NfG on minimising the TSE risk It DOES NOT certify that the quality of the substance can be suitably controlled by the Ph.Eur. monograph It DOES NOT certify that a batch of the substance complies with the monograph It IS NOT a GMP certificate P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

All CEPs specify: Unique Reference number (e.g. R0-CEP Rev01) Title: clear definition of the substance + grade when requested (eg. micronised, sterile,…) Holder + manufacturing site(s) Monograph(s) concerned Starting validity date Line numbering and annex details if appropriate P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

And as necessary, chemical CEPs: Additional impurities/Solvents/Catalysts –With limits and methods Re-test period –With storage conditions + container Specs (limit + test) for a specific grade Tests of the monograph which can be omitted Use or non-use of materials of animal origin P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

And if for a sterile material: Description of sterilisation method and container/closure Statement that the validation of the sterilisation has been evaluated NB: the information on the sterilisation process and its validation needs to be submitted separately in the marketing authorisation dossier P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

And for a TSE certificate: Country(ies) of origin of animals Animal and nature of tissue(s) used Manufacturing process applied (when relevant, e.g. gelatins) Quality assurance system applied P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

The CEP looks like: P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

How to use a CEP ? P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certification pages Certification on-line database Useful links Contacting us P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved Finding information on the Certification Procedure

P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Homepage - Finding your way Six main groups to help visitors find information directed at them. They are: EDQM: Latest news & general Information about the EDQM HealthCare: Blood Transfusion & Organ Transplantation activities European Pharmacopoeia: Commission & Work Programme, Reference Standards & Biological Standardisation Programme (BSP). P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Homepage - Finding your way (cont) Certification of Pharmaceutical Substances: Procedure of Certification (CEP) Control of Medicines: OMCL Network, PTS Studies, etc Products & Services: Publications, Reference Standards (Ph. Eur. & WHO ISA) & Certification P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certification pages P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved Click on the links within the main areas Place mouse on the top menu to open the submenus

Certification / News and General Information (1) P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved Click on the links within the submenus

P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved Certification/News and General Information (2)

Certification/New Applications P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certification/New Applications P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certification/Revisions and Renewals P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certification On-Line Database (1) P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certification On-Line Database (2) P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Here is an example of the information provided Our databases are linked, clicking on the monograph number takes you into our Knowledge Database Certification On-Line Database (3)

Certification On-Line Database (4) P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved From our Knowledge Database, you can also see other information

How to contact us ? For general queries for which the answer is not in the FAQs, you can contact us via the helpdesk. For application specific queries you can contact us via the address which we include in our communications about your application: P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Key figures P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certificates of suitability > 3700 applications since procedure launched ~ 2250 valid certificates > 760 substance monographs involved … P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certificates of Suitability … > 560 manufacturers from 43 countries P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Recent developments 1.Validation of new applications at receipt (= completeness check) Implemented in 2007Implemented in 2007 Both administrative & technical informationBoth administrative & technical information Performed within 8 days of application receiptPerformed within 8 days of application receipt If dossier complete: AR --> evaluation clock startsIf dossier complete: AR --> evaluation clock starts P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Recent developments 2.Closing of sleeping dossiers (dossiers lying dormant for months without reply) Applicants are given 6 months to provide additional information following a deficiency letterApplicants are given 6 months to provide additional information following a deficiency letter If no response : dossier closedIf no response : dossier closed P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Recent developments 3.Streamlined evaluation procedure (From September 2008) 1 deficiency letter only1 deficiency letter only if responses unsuitable  dossier closedif responses unsuitable  dossier closed P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Recent developments 4.Electronic submission (from September 2009): EncouragedEncouraged For all types of submissionsFor all types of submissions e-CTD, or NEES suitably bookmarked e-CTD, or NEES suitably bookmarked Check regularly EDQM website forinstructionsCheck regularly EDQM website forinstructions Paper OR electronic (no longer both)Paper OR electronic (no longer both) P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Recent developments 5.Manufacturing sites mentioned on CEPs When manufacturer of API purchases crude or late intermediate and performs only a final purification or salification, the site(s) of manufacture of the purchased material(s) will be mentioned on the CEP;When manufacturer of API purchases crude or late intermediate and performs only a final purification or salification, the site(s) of manufacture of the purchased material(s) will be mentioned on the CEP; GMP apply to manufacturer(s) of crude or late intermediate;GMP apply to manufacturer(s) of crude or late intermediate; Declarations to be submitted;Declarations to be submitted; Also applicable to post-production operations (micronisation or sterilisation), when these are claimed and approvedAlso applicable to post-production operations (micronisation or sterilisation), when these are claimed and approved P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Certification: benefits Single & harmonised assessment Replaces Active Substance Master File Savings of time and resources Updating of monographs (impurities) Revision of monographs (new or replacement test methods) CEPs are recognised in Europe and abroad P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved

Thank you ! P.Poukens-Renwart, 05/09/09 ©2009 EDQM, Council of Europe, All rights reserved